ArticleThe journal of vascular access2026
Tetrasodium EDTA central venous catheter lock solution in home parenteral nutrition patients: Ease of use and patient satisfaction, a prospective study.
Article in The journal of vascular access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic intestinal failure is a devastating chronic medical condition, which requires central venous access for parenteral nutrition infusion. The presence of a central venous line is associated with an increased risk of bloodstream infection and thrombosis. Currently, the heparin lock is the most used catheter lock, but still has risks for line infection. The 4% tetrasodium EDTA catheter lock (KiteLock™) solution, has demonstrated a decrease in infection and thrombosis risk, but requires extra steps for the preparation and infusion. The objective of this study was to evaluate the patients ease-of-use and acceptability of the new KiteLock solution in the home parenteral nutrition (HPN) patients.
methodsThis prospective, open-label, single-center study evaluated patient acceptability of tetrasodium EDTA (KiteLock) in HPN. Patients were contacted four times, beginning with an instructional visit by the HPN nurse. They then completed three 30-day phases: standard heparin/saline flush, tetrasodium with withdrawal (when feasible), and tetrasodium EDTA. During the final week of each phase, patients completed a phone survey and questionnaire with the HPN nurse.
resultsOf the 21 patients enrolled, 14 completed the study. Seven did not: two withdrew due to time constraints, two found KiteLock difficult to infuse, and three had incomplete data. Among those who competed the study, some reported reduced ease-of-use with KiteLock (1 hard to open, 5 difficulties withdrawing, 1 overall difficulty), though most still rated it easy or very easy. Three patients continued to find it more difficult by study end. No adverse effects were reported. Preparation time decreased over time as patients adapted. Initial satisfaction with KiteLock was lower (50% find it neutral), but improved with familiarity, becoming comparable to heparin with 12 patients satisfied (
conclusionsKiteLock solution is well accepted by the patient or caregiver, despite involving more steps to use it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.